Oral Antibiotics Alone in Children Aged 4 Weeks to 2 Months With a Urinary Tract Infection
Launched by RIGSHOSPITALET, DENMARK · Apr 14, 2023
Trial Information
Current as of August 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether giving oral antibiotics alone is safe and effective for young children, aged 4 weeks to 2 months, who have a urinary tract infection (UTI). The researchers want to find out if this method works well for children who are stable and don’t have a history of serious health issues. To be eligible for the study, children must show signs of a UTI, like having bacteria in their urine, but they should not be experiencing severe health problems or have a past of frequent UTIs or other related medical conditions.
If a child is chosen to participate, they will receive oral antibiotics without any other treatments. The study is currently looking for participants, and it aims to help doctors understand better ways to treat UTIs in young children. Parents can expect their child to be closely monitored during the study to ensure their safety and well-being. Overall, this trial could provide important insights into treating UTIs in infants safely and effectively.
Gender
ALL
Eligibility criteria
- INCLUSION CRITERIA:
- • 1. Clinical suspicion of urinary tract infection irrespective of the presence of fever.
- • 2. Clinically stable (i.e., not respiratory or circulatory affected, septic, or meningeal).
- • 3. 4 weeks to 2 months of age (corrected age, if premature).
- • All children who do not receive any empirical antibiotic therapy but have a positive urine culture can be included if the clinical suspicion of urinary tract infection persists.
- A positive urine culture is defined as:
- • Suprapubic bladder aspiration: any growth of bacteria.
- • Sterile intermittent catheterization: monoculture with ≥10\^3 colony forming units per milliliter (cfu/ml).
- • Midstream urine x 2: monoculture with the same bacteria in both tests with ≥10\^4 cfu/ml.
- • Midstream urine x 2: monoculture with the same bacteria in both tests with ≥10\^5 cfu/ml in one test and 10\^3 cfu/ml in another test.
- EXCLUSION CRITERIA:
- • 1. Non-Danish civil registration number.
- • 2. High-risk medical history.
- • 1. Previous urinary tract infection.
- • 2. Prophylactic antibiotic treatment.
- • 3. Known urogenital abnormality (i.e., hydronephrosis (pyelectasis ≥10 mm or/and caliectasis ≥5 mm); hydroureter; vesicoureteral reflux; multicystic dysplasia; renal dysplasia; renal hypoplasia; renal agenesis; duplex kidney; ectopic placed kidneys; polycystic kidney disease; neurogenic bladder dysfunction; and hypospadias).
- • 4. Previous hospitalization needing antibiotic therapy.
- • 3. Markedly elevated c-reactive protein indicating bacteremia.
- • 4. Elevated creatinine.
- • 5. Oral therapy is not possible (e.g., frequent vomiting or excessive regurgitation).
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hvidovre, , Denmark
Herlev, , Denmark
Hillerød, , Denmark
Copenhagen, , Denmark
Patients applied
Trial Officials
Naqash Sethi, MD
Principal Investigator
Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark
Ulrikka Nygaard, Ass. prof, Ph.D.
Study Chair
Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported